REVIEW Cell-based therapy for insulin-dependent diabetes mellitus

Insulin-secreting pancreatic b-cell lines represent a promising approach for treatment of insulin-dependent diabetes mellitus. Such cell lines can provide an abundant and reproducible source of b-cell material for transplantation. A number of highly differentiated b-cell lines have been developed using transgenic mice. These cells produce insulin amounts comparable to normal pancreatic islets and release it in response to physiological insulin secretagogues. Our laboratory has employed a reversible transformation approach to tightly regulate cell replication in these b-cell lines, both in culture and in vivo. Beta-cell lines can be modulated by gene transfer to improve their function and survival. We have utilized adenovirus genes, which downregulate antigen presentation and increase cell resistance to cytokines, to facilitate transplantation of mouse b cells across allogeneic barriers. These approaches could be applied to the development of human b-cell lines by genetic engineering of isolated human islets. European Journal of Endocrinology 138 129–13